<?xml version="1.0" encoding="UTF-8"?>
<p id="p0010">GH is one of the most prevalent sexually transmitted diseases. More than 500 million people worldwide are infected with GH, and 20–23 million new infections are reported each year according to WHO (
 <xref rid="bib31" ref-type="bibr">Kesharwani et al., 2017</xref>). As a member of the herpesvirus family, HSV-2 is the primary causative agent of GH (
 <xref rid="bib46" ref-type="bibr">Mousavi et al., 2017</xref>). HSV-2 is a giant dsDNA virus belonging to the α-herpesvirus subfamily, which is mainly transmitted to genital mucosa through sexual behavior. HSV-2 causes genital herpes or ulcers during acute infection (
 <xref rid="bib31" ref-type="bibr">Kesharwani et al., 2017</xref>, p. 2), and can migrate to cranial ganglia resulting in lifelong latent infection (
 <xref rid="bib36" ref-type="bibr">Liu et al., 2018</xref>). HSV-2 infection during early pregnancy can also cause neonatal encephalitis through placental transmission, resulting in high morbidity and mortality (
 <xref rid="bib60" ref-type="bibr">Vilhelmova-Ilieva et al., 2014</xref>). Epidemiological studies have shown that HSV-2 can act as an important synergistic factor for human immunodeficiency virus (HIV) and human papillomavirus (HPV) infection (
 <xref rid="bib48" ref-type="bibr">Nikolic and Piguet, 2010</xref>), and increase the risk of HIV-1 infection by 2–3-fold (
 <xref rid="bib45" ref-type="bibr">Mohraz et al., 2018</xref>). The prevention and treatment of GH has always been an urgent problem to be solved.
</p>
